Table 3.
Changes in obesity‐related risk factors
| Usual care (N = 82) | NB + CLI (N = 71) | P | |
|---|---|---|---|
| LS mean change (SE) from baseline at week 26 | |||
| Waist (cm) | −1.6 (0.66) | −7.0 (0.71) | <0.0001 |
| Triglycerides (mg/dL) | 2.8 (4.63) | −13.6 (4.96) | 0.0019 |
| HDL cholesterol (mg/dL) | 0.1 (0.73) | 4.1 (0.77) | 0.0001 |
| LDL cholesterol (mg/dL) | −1.9 (2.11) | −2.0 (2.20) | 0.9686 |
| Fasting plasma glucose (mg/dL) | 1.6 (0.96) | −2.9 (1.04) | 0.0016 |
| Fasting insulin (µIU/mL) | −3.4 (0.76) | −7.5 (0.79) | 0.0004 |
| HOMA‐IR | −0.8 (0.19) | −2.0 (0.20) | 0.0003 |
| Mean change (SE) from baseline at week 78 (all subjects with week 78 data) (N = 83) | |||
| Waist (cm) | −7.5 (0.81) | ||
| Triglycerides (mg/dL) | −12.4 (8.17) | ||
| HDL cholesterol (mg/dL) | 7.0 (0.94) | ||
| LDL cholesterol (mg/dL) | 0.3 (2.32) | ||
| Fasting plasma glucose (mg/dL) | −0.8 (1.10) | ||
| Fasting insulin (µIU/mL) | −7.9 (2.51) | ||
| HOMA‐IR | −1.9 (0.67) | ||
P value for ANCOVA LS mean difference between treatment groups.
CLI, comprehensive lifestyle intervention; HDL, high‐density lipoprotein; HOMA‐IR, homeostasis model assessment of insulin resistance; LDL, low‐density lipoprotein; LS, least squares; SE, standard error.